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Abstract 
 
Aims 
Studies have shown that health service utilization often increases in few years immediately 
before death.  Estimates of direct medical cost of diabetes mellitus (DM) in mortality year 
and the previous year is not well understood. This study aimed to report the health resource 
use and estimate the direct medical costs among DM patients in the year of mortality and the 
year before mortality. 
 
Materials and Methods 
We analysed a population-based, retrospective cohort study including all adults with DM 
diagnosis in Hong Kong between 2009 and 2013, and death between January 1, 2010 and 
December 31, 2013. Annual direct medical costs in year of mortality and year before 
mortality were determined by summing costs of health services utilized within the respective 
year. The costs were analysed by gender, the presence of co-morbidities, diabetic 
complications and primary cause of death.  
 
Results 
A total of 10,649 patients met the eligibility criteria for analysis. On average, the direct 
medical costs in the year of death were 1.947 times higher than those in the year before death. 
Male and female patients had similar costs in the year before mortality and mortality year. 
Patients with any diabetic complications had greater costs in the year of mortality and before 
mortality than those without. 
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Conclusions 
This analysis provides new evidence on incorporating additional direct medical costs in the 
mortality year, and refining the structure of total cost estimates for use in costing and cost-
effectiveness analyses of interventions for DM.  
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Manuscript Text 
Introduction 
 
Due to the population ageing, environmental and lifestyle changes, the global prevalence of 
diabetes mellitus (DM) in adults was 8.8% in 2015, and has been predicted to increase to 
10.4% in 2040 [1]. The mean healthcare expenditure for each adult living with DM was 
US$1,583 in 2014, projecting an annual healthcare expenditure attributable to DM ranging 
between US$612-1,099 billion worldwide [2].  
 
Direct medical costs have important implications for the implementation of health care 
interventions regarding the prevention of diabetes and diabetes-related complications. 
Estimations of the lifetime direct medical costs of DM quantifies economic burden and 
consequences to national healthcare services. A United States national retrospective study 
estimated lifetime medical expenditures for DM patients from diagnosis to death [3]. Results 
from UK Prospective Diabetes Prospective Study [4] reported that patients with diabetes-
related complications incurred more annual direct medical costs than those without. Another 
study based on multiple data sources in the US reported the total number of deaths 
attributable to DM, and estimated the indirect cost due to early mortality [5]. The largest 
direct medical cost component was hospital inpatient care, followed by outpatient care and 
allied health care. Premature mortality attributed to DM equated to US$18.5 billion in 2012 
[5]. Among 246,000 deaths in 2012 attributable to DM, about 55% and 28% of them had 
renal failure and cerebrovascular disease recorded as the primary causes of death, suggesting 
that high direct medical costs at mortality year may result from healthcare due to diabetes-
related complications.  
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With prevailing number of co-existing morbidities or complications over the survival years, 
thereby leading to morbidity compression and drastic rise in healthcare resource use [6], the 
direct medical costs in the year of death was thought to be greater than those costs in the 
survival years. The time-to-death variable plays an important role in cost  models for chronic 
diseases [7]. Although access to population-based database on healthcare utilization enables 
us to examine direct medical costs and their determinants, there have been no published 
studies that report direct medical costs in the year of death and compare them with costs in 
the survival years.  
 
This study aimed to report the health resource utilization and estimate the direct medical 
costs among patients with DM in the year of mortality and the year before mortality. We 
examined the influence of the primary causes of death and the presence of diabetes-related 
complications on the direct medical costs, allowing for better projections of medical 
expenditures attributable to DM patients. 
 
Materials and Methods 
 
Study design and patient sampling 
 
The population-based, retrospective cohort data, of those patients who had visited primary 
care general outpatient-clinics in Hong Kong Hospital Authority between August 1, 2008 and 
December 31, 2013, were extracted from Hospital Authority administrative database. 
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Inclusion criteria of patients were 1) aged 18 and over; and 2) documented diagnosis of DM 
(defined by the ICPC-2 codes T89/T90) on or before January 1, 2009. A cohort of 161,469 
DM patients was selected based on aforementioned inclusion criteria. To assess the cost of 
mortality year and the year before mortality, only patients who died between Jan 1, 2010 and 
December 31, 2013 were included. A total of 10,649 DM patients dying between January 1, 
2010 and December 31, 2013 were included in final data analysis of the mortality year cost 
estimation (Supplemental Figure 1). While the data inclusion period started from August 
2008, patients who died between January 1, 2010 and 1 August 2010 were not utilized for the 
data analysis of the year before mortality cost estimation. 
 
The International Statistical Classification of Diseases and Related Health Problems, 10th 
Revision (ICD-10) diagnosis codes were used to identify the primary cause of death, whereas 
the diabetes-related complications were identified by the International Statistical 
Classification of Diseases and Related Health Problems, 9th Revision, Clinical Modification 
(ICD-9-CM) and the International Classification of Primary Care, Version 2 (ICPC-2) codes 
as listed in Supplementary table 1 and Supplementary table 2.  
 
Estimation of annual direct medical costs 
 
This cost analysis adopted the same approach in a previous study [8]. Frequency of 
healthcare service utilization within Hospital Authority of each patient at the mortality year 
and the years before mortality were retrieved from the Hospital Authority administrative 
database. Cost items included general outpatient visits, specialist outpatient visits, emergency 
visits, and length of hospital stay at general ward, intensive care unit, and high dependency 
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unit. The unit cost of each type of healthcare service was based on the price list for non-
eligible persons, published in 2013 Government Gazette and Hospital Authority Ordinance 
[9]. Annual direct medical costs were calculated for each patient as follows: annual direct 
medical costs = Ȉ number of unit of each healthcare service item x unit cost of respective 
healthcare service item. 
 
Patient covariates 
 
The covariates of the DM patients included gender, group of death age, ethnicity, type of 
diabetes, the presence of co-morbidities, the presence of diabetes-related complications, and 
the primary cause of death. 
 
Death age was categorized into four groups: <65 years, 65-74 years, 75-84 years and  
years. The ethnicity was divided into ³&KLQHVH´ and ³QRQ-&KLQHVH´ Type of diabetes was 
identified by ICPC-2 codes ³7´ for insulin dependent diabetes (Type I diabetes) and ³T90´ 
for non-insulin dependent diabetes (Type II diabetes). The level of co-morbidities was 
measured by the Charlson Comorbidity Index (CCI) [10]. The Charlson comorbidities for 
DM with and without chronic complications were excluded from the CCI calculation to avoid 
double-counting. Existence of each co-morbidity was scored and a final score was calculated 
by summing all the points. The CCI was categorized into four groups: 0, 1, 2 and  
 
Association between annual direct medical cost and the presences of nine diabetic 
complications (acute myocardial infarction, other ischemic heart disease, congestive heart 
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failure, stroke, peripheral vascular disease, diabetic retinopathy, diabetic nephropathy, end-
stage renal disease, and diabetic foot ulcer) were tested. Other diabetes-related complications 
(amputation, lower limb ulcer, blindness, diabetic neuropathy and sight-threatening diabetic 
retinopathy) with low observation counts (<2%) were not controlled for regression analysis. 
Because of the limited number of patients in some groups for primary causes of death, a total 
of seven groups including infectious and parasitic diseases, neoplasms, diseases of the 
circulatory system, diseases of the respiratory system, diseases of the digestive system, 
diseases of the genitourinary system, and others were divided. 
 
Statistical analysis 
 
Annual direct medical costs, their 95% confidence intervals and the proportion of the cost of 
hospitalization of patients with DM at 48-60 months before mortality, 36-48 months before 
mortality, 24-36 months before mortality, 12-24 months before mortality, and the mortality 
year were calculated. 
 
Furthermore, healthcare resource use and annual direct medical costs at the year of mortality 
and the year before mortality (12-24 months before mortality) were analysed by the 
covariates, which are gender, age group, the presence of co-morbidities, the presence of 
diabetic complications (heart disease, stroke, diabetic nephropathy, or diabetic retinopathy), 
and primary cause of death. 
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Generalized linear models with an identity-link function and log-link function with gamma 
distribution were used to explore the associations of the annual direct medical costs. Both the 
log-link function and identify-link function in the generalized linear model were used for 
estimations of direct medical costs, in line with previous costing study [8]. Coefficients, 
multipliers (exponential value of coefficient) and their corresponding 95% confidence 
intervals for each covariate were reported. In comparing the goodness-of-fit of generalized 
linear models with an identify-link and log-function, the mean absolute error (MAE) and the 
root-mean-square error (RMSE) of the each model were be calculated. A smaller MAE and 
RMSE indicate a better model fit. 
 
All statistical analyses were performed using STATA version 13.0 (StataCorp LP, College 
Station, TX, USA). All VLJQL¿FDQFH tests were two-tailed and P values < 0.05 were taken to 
indicate statistical VLJQL¿FDQFH 
 
Results 
 
Patient characteristics 
A total of 10,649 patients with documented diagnosis of DM at least one year before 
mortality were identified. The mean death age of the patients was 79.4 (with S.D. 10.6) and 
the distribution of the gender was nearly fifty-fifty (with male 49.36% and female 50.64%). 
96.69% of the patients were Chinese and nearly all of the patients were non-insulin 
dependent diabetes (99.88%). Nearly two-third of the patients (62.19%) suffered from at least 
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one of diabetic complications and the most common primary cause of death was Neoplasms 
(28.41%) (Supplementary table 3). 
 
Costs in the mortality year and years before mortality 
Annual direct medical costs, their 95% confidence intervals and the proportion of the cost of 
hospitalization of patients with DM in the mortality year and the years before mortality are 
presented in Figure 1. The closer the mortality year, the higher the annual direct medical 
costs and the proportions of the hospitalization cost over the annual direct medical cost were. 
The average medical cost in the year of mortality doubled from US$11,807.0 (73.7% for 
hospitalization cost) to US$22,987.5 (78.4% for hospitalization cost) in the year of mortality 
(Figure 1). Given the costs in 48-60 months before mortality, 36-48 months before mortality 
and 24-36 months before mortality are roughly similar while the costs in 12-24 months 
before mortality and the mortality year are much higher, the detailed results are only 
presented for the year before mortality (12-24 months before death) and the year of mortality. 
 
Utilization of healthcare services 
Frequencies of healthcare services attendance for each patient in the year before mortality 
and in the year of mortality were measured, respectively. The mean number of general 
outpatient clinic and specialist outpatient clinic visits in the year before mortality were 
greater than that of in the mortality year (5.0 times and 4.7 times vs 2.4 times and 3.9 times, 
respectively). However, mean number of nights of hospital stay at general ward in the 
mortality year was much greater than that in the year before mortality (27.7 nights vs 13.8 
nights). Mean number of nights of hospital stay at intensive care unit and critical care unit in 
the mortality year were also greater than that in the year before mortality (0.4 nights and 0.1 
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nights vs 0.1 nights and 0 nights respectively) (Table 1). Since unit costs of hospital stay at 
general ward, intensive care unit and high dependency unit were at least four times of that of 
general outpatient clinic and specialist outpatient clinic visit [9], the annual direct medical 
cost in the mortality year was higher than that in the year before mortality. 
 
Comparison of the annual direct medical cost by time and existence of covariates 
Table 2 shows the influence of the SDWLHQWV¶ covariates on the annual direct medical cost.  
 
The female patients had a similar medical cost compared with the male patients in the year 
before mortality (US$11,980.6 vs US$11,628.8; p=0.440) and in the mortality year 
(US$22,825.4 vs US$23,153.8; p=0.543).  The medical costs were almost double in the 
mortality year compared to the year before for both male and female (Table 2). 
 
Analysed by age group, the group with the highest cost in the year before mortality was 
patients aged 85 or above (US$12,172.1) and the group with the highest cost for the mortality 
year patients aged 65-74 (US$24,459.9). The medical costs in all age groups were nearly 
double in the mortality year (1.94 times for aged below 65; 2.27 times for aged 65-74; 1.97 
times for aged 75-84; 1.76 times for aged 85 or above) (Table 2). 
 
By ethnicity, higher medical costs were recorded for Chinese patients in both year before 
mortality and in the mortality year (US$11,992.6 and US$23,216.6 for Chinese patients; 
US$6,394.0 and US$16,304.5 for non-Chinese patients, respectively). The costs in the 
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mortality year in two groups were doubled compared to the costs in the year before mortality 
(1.94 times for Chinese; 2.54 times for non-Chinese) (Table 2). 
 
For type of diabetes, patients with non-insulin dependent diabetes had significantly higher 
medical costs in the mortality year than the year before mortality (US$22,988.8 vs 
US$11,819.2; p<0.001), but insignificantly higher costs for patients with insulin dependent 
diabetes in both years (US$23,789 vs US$14,525.9; p=0.1236) (Table 2). 
 
Analysed by the levels of co-morbidities, the higher the CCI score, the higher medical cost in 
the mortality year. The medical cost in the mortality year was increased 1.5 times compared 
to the year before mortality, regardless of the CCI scores (1.96 times for score 0; 1.61 times 
for score 1; 2.17 times for score 2; 1.84 times for score 3 or above) (Table 2). 
 
Patients with at least one of the diabetes-related complications had higher costs than those 
without both in the year of mortality (US$24,585.6 vs US$20,358.5) and the year before 
mortality (US$13,509.0 vs US$9,007.1). The medical costs in the mortality year were two 
times of the costs in the year before mortality (1.82 times for patients with any diabetic 
complications; 2.26 times for patients without diabetic complication) (Table 2). 
 
The most costly primary cause of death in the year before mortality was diseases of the 
genitourinary system (US$16,696.4), whereas the most costly primary cause of death for the 
mortality year was certain infectious and parasitic diseases (US$32,989.0). The ratio of the 
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costs in the mortality year to the costs in the year before mortality varied from 1.43 to 3.35 
times (Table 2). 
 
Association between the annual direct medical costs and SDWLHQWV¶ covariates 
Table 3 and Table 4 show the estimated coefficients of the effect of covariates on direct 
medical costs of patients with DM using the generalized models with identify link and log 
link, respectively.  
 
a) Fitting a generalized linear model using the identity link with gamma distribution 
From table 3, the base case annual average medical cost was US$6,005.7 in the year before 
mortality (85-year-old or elder male patient without any diabetic complications died with 
other primary cause of death). Female DM patients were expected to cost US$531.5 more 
than male DM patients. The patients aged below 65 paid US$1,990.5 more while the patients 
aged 65-74 paid US$340.4 less compared to those aged 85 or above. Moreover, nearly all the 
presence of diabetes-related complications increased the direct medical cost. DM patients 
with diabetic foot were expected to cost US$9,055.0 more than the patients who do not. 
Patients with diabetic retinopathy would cost US$577.5 less than the patients who do not but 
the difference was not statistically significant. The patients that died due to diseases of the 
genitourinary system and diseases of the respiratory system would cost US$3,574.9 and 
US$5,097.1 more than patients with other primary cause of death respectively. 
 
In the year of mortality, the base case annual average inpatient cost was US$8,283.1. The 
average medical cost of female patients was US$767.1 higher than that of male patients. DM 
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patients aged 65-74 and aged 75-84 paid US$1,329.1 and US$1,143.2 more than the patients 
aged 85 or above respectively. The presence of any of the diabetes-related complications 
increased the direct medical cost (ranging between an increase of US$512.3 for the presence 
of acute myocardial infarction and an increase of US$13,479.0 for the presence of diabetic 
foot).  The patients that died due to certain infectious and parasitic diseases and neoplasms 
would cost US$18,218.2 and US$15,792.1 more than patients with other primary causes of 
death respectively. 
 
b) Fitting a generalized linear model using the log link with gamma distribution 
Table 4 presents the base case annual average medical cost was US$6,172.2 in the year 
before mortality (85-year-old or elder male patient without any diabetic complications died 
with other primary cause of death). Female DM patients had a higher cost than male patients 
with a multiplier 1.037. Compared with the patients aged 85 or above, all the patients in other 
age groups had higher costs (with multipliers 1.357, 1.060 and 1.060 for patients aged 65 
below, 65-74 and 75-84 respectively). The most costly diabetic complication and the most 
costly primary cause of death were diabetic foot ulcer (with a multiplier 1.766) and diseases 
of the respiratory system (with multiplier 1.547), respectively.  
 
At the year of mortality, the base case annual average medical cost was US$9,891.8. The cost 
of the female patients was higher than that of male patients (with a multiplier 1.020). Patients 
below 85 years old would cost more than the patients aged 85 or above (with multipliers 
1.131, 1.164 and 1.099 for patients aged 65 or below, 65-74 and 75-84 respectively). All the 
presence of diabetic complications would have a positive relationship on the medical cost, 
where the most costly diabetic complication was diabetic foot ulcer (with a multiplier 1.660). 
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The most costly primary cause of death is certain infectious and parasitic diseases (with a 
multiplier 2.369). 
 
c) Goodness-of-fit of models  
Both the MAE and RMSE of the generalized linear model using the identity link with gamma 
distribution are smaller than the generalized linear model using the log link with gamma 
distribution (The year before mortality ± MAE: 13,171.4 vs 13,266.8, RMSE: 222.9 vs 260.1; 
The mortality year ± MAE: 17,737.8 vs 17,877.9, RMSE: 223.8 vs 261.4). Therefore, the 
generalized linear model using the identity link with gamma distribution was preferred over 
that using the log-link with gamma distribution. 
 
Discussions 
 
To quantify burden of DM to healthcare provider, healthcare resource use and annual direct 
medical costs were estimated using routine administrative database in many developed 
countries such as US [3, 11], United Kingdom [4, 12], Denmark [13], Australia [14], Sweden 
[15], and Singapore [16]. Nevertheless, aforementioned studies primarily assessed the impact 
of diabetes-related complications on healthcare costs while the present study utilized the 
patient-level data within hospital administrative database, and reported the robust estimates 
of annual direct medical costs at mortality year and years before the mortality. Importantly, 
annual direct medical costs in the mortality year (US$22,987.5) were almost double of those 
in the year before mortality (US$11,807.0), echoing to the notion ³WKH high cost of G\LQJ´ 
[17] that the annual healthcare costs of those DM patients in their last year of life were 
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greater than those of DM patients who survived. High costs in the mortality year were 
possibly due to the occurrence of diabetes-related complications. Evidence from diabetes 
models (e.g. UKPDS 82[18]) demonstrated that DM patients had higher probability of death 
in the first year of complication event. Healthcare costs of patients having complication event 
(s) occurred in the first year were significantly greater than those of those without 
complication event occurred. Our costing analysis provided evidence on incorporating 
additional amounts into direct medical cost estimation in the mortality year, especially when 
a complication event occurs. Furthermore, the proportion of hospitalization cost increased 
with the decrease in life expectancy from 73.7% in the year before mortality to 78.4% in the 
year of mortality, indicating the switch of healthcare service utilization from primary care 
setting to hospital-based setting for those who had shorter life expectancy. 
 
The present study investigated the association between annual direct medical cost and the 
patient characteristics. Based on regression results, substantial impacts of co-morbidities, 
diabetes-related complications and primary cause of death on annual direct medical costs 
were observed. Patients with presence of the diabetic ulcer foot had the highest incremental 
annual direct medical costs, with US$13,479.0 more than those who did not (in generalized 
linear model with identity link of gamma distribution) or 1.660 times more than those who 
did not (in generalized linear model with log link of gamma distribution). The costs 
associated with diabetic ulcer foot in the event and subsequent years were not derived in most 
of the costing analyses[3, 4, 12, 13, 16], whereas diabetic ulcer foot was part of the broad 
category such as peripheral circulatory complications[15] in one Swedish study. However, as 
demonstrated in current study, the diabetic foot ulcer was one of the most expensive diabetes-
related complications, in line with previous retrospective cohort studies[8, 11, 14]. Besides, 
among types of primary death cause, DM patients who died because of certain infectious and 
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parasitic diseases had the highest incremental annual direct medical costs in the mortality 
year (US$18,218.2). Of those, more than 80% patients (83.5%) died due to that category 
were classified as sepsis.  
 
In light of healthcare resource use in public sector, DM patients in their mortality year had 
less utilization of outpatient visits and allied health professional visits than those in the year 
before mortality. Reciprocally, patients in the mortality year utilized more emergency visits 
and hospitalization in term of general wards and intensive care unit than those in the year 
before mortality. Towards the mortality year, DM patients relied on secondary care delivered 
by hospitals rather than primary care mainly delivered by outpatient clinics.  In addition to 
age and composition of multi-morbidity, the time-to-death was determinants of healthcare 
utilization and direct medical costs in DM patients, supported by previous study [7]. Hence, 
healthcare utilization pattern presented in current study would help policy-makers to advocate 
the healthcare service planning and allocation according to life expectancy and time-to-death 
information of DM patients. 
 
Another implication of our findings was significant increase in the healthcare costs in 
mortality year in comparison to those in the year before mortality. Differences in accrued 
health costs between the two years provided a strong argument for the refinement of the cost 
structure in costing and cost-effectiveness analysis of health interventions for DM. 
Conventionally, cost-effectiveness modelling assumed that the Hong Kong healthcare costs 
in DM patients were the same over the time horizon, and do not account for the differences in 
healthcare costs between the mortality and non-mortality years [19-22]. Therefore, evidence 
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from this study supports the adjustment on direct medical costs in the mortality year and year 
before mortality in future cost-effectiveness analyses. 
 
Limitations 
Several limitations and assumptions must be acknowledged. Firstly, unit costs of healthcare 
service item were obtained from published documents at Hong Kong Government Gazette, 
whereby no temporal adjustment or inflation was taken into consideration. Each patient was 
assumed to have the same unit cost of healthcare service item, as a packaged price inclusive 
of consultation, investigations, prescribed medications, radiology, and other examinations 
during the clinic visit or hospital stay. Actual resource use for each healthcare service item, in 
term of human resource, equipment, consumables, and overhead, were assumed to be the 
same. As such, the annual direct medical costs in the death year and years before death might 
be biased, and valid for Hong Kong DM patients and for the time period when unit costs of 
healthcare service are still current. Secondly, current analysis estimated public healthcare 
utilization and corresponding annual direct medical cost attributable to DM patients, adopting 
government-based public healthcare provider perspective. Resource use in private sector and 
indirect costs based upon productivity losses were not taken into consideration. Finally, the 
cause of the healthcare resource use is an important issue for consideration. Especially for 
elderly DM patients, a proportion of healthcare resource use and costs might be unrelated to 
DM or diabetes-related complications However, our retrospective cohort data are not possible 
to differentiate the cause of the healthcare resources uses, and not possible to determine 
whether the healthcare resources uses are due to primary cause of death or diabetic 
complications. 
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Conclusions 
The annual direct medical costs of DM patients in the mortality year were almost two times 
greater than those in the year before mortality. Healthcare costs in both the mortality year and 
the year before mortality were influenced by the presence of diabetes-related complications 
and primary cause of death. This analysis provides new evidence on incorporating an 
additional direct medical cost in the mortality year, and refining the structure of total cost 
estimates for use in costing and cost-effectiveness analyses of health interventions for DM. 
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Figure Legend 
 
Figure 1: Average annual direct medical costs of patients with diabetes mellitus and 
proportion of the cost of hospitalization at 48-60 months before mortality, 36-48 months 
before mortality, 24-36 months before mortality, 12-24 months before mortality, and the 
mortality year. Error bars indicated their 95% confidence intervals.  
